FY2025 EPS Estimate for BioLife Solutions Boosted by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Northland Capmk lifted their FY2025 earnings per share estimates for shares of BioLife Solutions in a report released on Friday, November 7th. Northland Capmk analyst C. Byrnes now forecasts that the medical equipment provider will earn $0.07 per share for the year, up from their previous estimate of $0.05. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share.

Several other analysts also recently issued reports on the stock. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Stephens began coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus target price of $31.29.

BioLife Solutions Stock Down 4.0%

Shares of BLFS stock opened at $25.93 on Monday. BioLife Solutions has a 12 month low of $19.10 and a 12 month high of $29.62. The business’s 50 day moving average is $26.55 and its two-hundred day moving average is $24.08. The company has a market cap of $1.24 billion, a PE ratio of -216.07 and a beta of 1.97.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The company had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million.

Insider Buying and Selling

In other news, CEO Greef Roderick De sold 37,795 shares of the stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $27.30, for a total transaction of $1,031,803.50. Following the sale, the chief executive officer owned 489,998 shares in the company, valued at approximately $13,376,945.40. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Troy Wichterman sold 1,032 shares of BioLife Solutions stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $27,688.56. Following the completion of the transaction, the chief financial officer directly owned 184,186 shares of the company’s stock, valued at $4,941,710.38. This represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 1,307,742 shares of company stock valued at $35,167,584. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Amalgamated Bank lifted its stake in shares of BioLife Solutions by 3.5% during the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 366 shares during the period. Ameritas Investment Partners Inc. increased its position in BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 441 shares during the period. Louisiana State Employees Retirement System raised its holdings in BioLife Solutions by 2.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock worth $454,000 after purchasing an additional 500 shares during the last quarter. Isthmus Partners LLC lifted its position in BioLife Solutions by 0.4% during the 2nd quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after purchasing an additional 509 shares during the period. Finally, Sei Investments Co. boosted its stake in shares of BioLife Solutions by 0.5% in the 1st quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock valued at $2,695,000 after purchasing an additional 547 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.